Using IP1 assays to study FGFR mediated pathways for cancer drug research

IP-one and intracellular signaling molecules explored with HTRF and AlphaLISA cell-based assay kits

Altered signaling pathways are involved in many cancer types, adding fuel to processes associated with uncontrolled growth and an increased ability to invade surrounding tissue. In order to develop efficient therapies to fight cancers, scientists must study how these dysregulated pathways respond to the drug candidate.

One of these pathways is FGFR mediated PLCγ signaling, identified in breast and prostate cancers. Inositor Triphosphate (IP3) is a signaling molecule in this pathway, and its metabolization results in D-myo-Inositol 1-Phosphate (IP1).

In this application note, scientists show how the detection of intracellular accumulation of IP1 can be used as a powerful way to characterize compounds modulating FGF receptor signaling in various cancer cell lines expressing FGFR1, FGFR2, and FGFR3.

Using our no-wash and automatable IP-One HTRF™ and AlphaLISA™  assays, scientists measured the activation status of intracellular downstream key enzymes and second messengers.

Featured in this application note:

• Assay principles and detailed workflows
• Informative materials and methods, including references
• Consistent results (data and graphs)

For research use only. Not for use in diagnostic procedures.